GTx muscle drug fails late-stage trials, shares plunge

(Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials, sending its shares plunging 67 percent. The drug, enobosarm, the most advanced in GTX's pipeline, also failed to improve physical function in patients, measured by improvement in their ability to climb stairs. A 3-mg dose of the drug was tested on about 325 patients with non-small cell lung cancer - the most common form of lung cancer. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/gtx-muscle-drug-fails-stage-trials-shares-plunge-132244676.html